Stem Cell Patents Come Under Fire
By Associated Press,
Associated Press
| 07. 19. 2006
MILWAUKEE -- A consumer group, a patent foundation and a stem cell scientist are challenging patents on human embryonic stem cells held by the Wisconsin Alumni Research Foundation.
The Public Patent Foundation, the Foundation for Taxpayer and Consumer Rights, and Jeanne Loring, a stem cell scientist at the Burnham Institute for Medical Research in California, claim that the patents hinder research, push scientists to pursue work overseas and represent a waste of taxpayer money.
"It's absolutely absurd that one person or organization could own the rights to life itself," said John Simpson, stem cell project director of the Foundation for Taxpayer and Consumer Rights, based in California.
The Wisconsin Alumni Research Foundation _ or WARF _ is the patenting and licensing arm of the University of Wisconsin. University researcher Jamie Thomson first isolated embryonic stem cells in 1998.
WARF director Carl Gulbrandsen said he was confident the patents are valid, saying the challenge was motivated by politics and money.
"WARF stem cell patents do not inhibit research," he said. "They support and encourage it."
Simpson, Loring and others announced their...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Alexandra Marquez, NBC News | 03.13.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump on Thursday blamed “the genetics” of assailants in a string of recent attacks across the country. He made the comments after attacks at a...
